Equibles does not estimate personal net worth.
Get an email with a short summary when Merck & Co., Inc. publishes a filing, an earnings call transcript or a press release.
Get MRK alertsRobert Davis is recorded as CFO at Merck & Co., Inc. (MRK). The proxy statement of Merck & Co., Inc. reports total compensation of $20,797,845 for Robert Davis in fiscal 2025, including a base salary of $1,645,302. Disclosed compensation is on record for 9 fiscal years. Robert Davis has spoken on 5 earnings calls across 1 company, most recently for Merck & Co., Inc. on October 30, 2025. Merck & Co., Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Merck & Co., Inc. includes Robert M. Davis (CEO, Chairman and Board Member), Jennifer Zachary (General Counsel), Dalton E. Smart III (Chief Accounting Officer) and 7 others.
“We continue to make meaningful progress in using the power of leading-edge science to save and improve lives around the world.”
“Yes, let me start by saying that we were very pleased with the overall tone and discussion coming out of the ACIP meeting. Regarding V116, we are confident in the strength of the data behind it.”
“We continue to make great progress in bringing forward compelling science to help address the world’s most urgent unmet medical needs. Thanks to the unwavering commitment and discipline of our global teams, we’re advancing our innovative pipeline and executing operationally in support of our key growth drivers.”
“We began 2023 with significant advancements across key areas of our pipeline and with continued strong performance of our key growth drivers. I remain very pleased with the consistency and excellence of our team's execution, and I'm confident that our strategy is leading to sustainable success.”
“I'm proud to report that the business continues to perform extremely well. We remain firmly guided by our strategic priorities to build long-term growth and deliver value to patients and shareholders.”
Drug Manufacturers - General · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,645,302 | $20,797,845 |
| 2024 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,623,874 | $23,186,064 |
| 2023 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,603,091 | $20,273,287 |
| 2022 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,538,613 | $18,650,093 |
| 2021 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,319,959 | $13,722,121 |
| 2020 | Merck & Co., Inc. (MRK) | Chairman, Chief Executive Officer and President | $1,112,795 | $6,839,510 |
| 2019 | Merck & Co., Inc. (MRK) | Chief Executive Officer, President and Former Chief Financial Officer | $1,075,557 | $7,727,188 |
| 2018 | Merck & Co., Inc. (MRK) | President and Former Chief Financial Officer | $1,043,726 | $6,620,840 |
| 2017 | Merck & Co., Inc. (MRK) | Executive Vice President, Global Services and Chief Financial Officer | $1,018,269 | $6,310,899 |
